Our solutions
XEMPERIA applies cutting-edge knowledges to redefine solutions for early cancer detection, monitoring and therapy selection, providing patients and physicians with vital information at all stages of the disease.
Currently XEMPERIA develops two solutions protected by two patent families:
- Breast cancer detection blood test is our most advanced product. The initial clinical study showed excellent and promising results for early breast cancer detection. XEMPERIA is now preparing a large-scale clinical study to validate the performance of the test. The final product will consist of a PCR kit compatible with standard IVD qPCR equipment, along with an algorithm for data interpretation.
- DNA-based nanosensors platform for rapid and sensitive detection of RNA and DNA molecules. Our initial focus is on developing this platform for Research Use Only (RUO) applications in oncology, cardiovascular, immuno-inflammatory, and neurodegenerative diseases, offering a rapid and cost-effective alternative to PCR and sequencing. Clinical applications will follow.
Our technologies are evolutive and adaptable to address additional clinical needs:
● Detection of many kinds of cancer. Early detection of other cancers that can benefit from early treatment.
● Stratify high- vs low-risk patients. Helping doctors choose the best therapy from the start.
● Patient monitoring. Rapidly detect progression and therapy adaptation.
● Monitorng patients with chronic conditions. These include inflammatory,
cardiovascular, neurological diseases.
Interested in knowing more?
- © 2025 Xemperia. All rights reserved | Imprint | Design: ZebraZbinden | Development: FRESCHI IT